[Form 4] Journey Medical Corporation Insider Trading Activity

Rhea-AI Filing Summary

Journey Medical Corp. (DERM) – Form 4 insider transaction

On June 25 2025, Director Dr. Lindsay A. Rosenwald received 7,173 restricted stock units (RSUs) at a cost of $0 under the company’s 2015 Stock Plan. The RSUs will vest in full on June 25 2026.

After this grant, Dr. Rosenwald beneficially owns 161,146 shares directly and 176,470 shares indirectly through a limited-liability company of which she is the managing member—an aggregate of 337,616 common shares. No shares were sold, and no derivative securities were involved.

The filing reflects routine equity compensation intended to align the director’s interests with shareholders. The grant size is modest relative to typical daily trading volume and does not materially affect the company’s share count or control structure.

Insights

Financial Analyst

TL;DR: Routine RSU grant; negligible dilution, neutral investor impact.

This Form 4 records a standard annual equity award—7,173 RSUs—to Director Dr. Rosenwald. Post-grant ownership rises to 337,616 shares (direct + indirect). Because the award represents an immaterial fraction of Journey Medical’s outstanding shares and involves no open-market purchase or sale, it neither signals insider bullishness nor raises dilution concerns. Overall, the disclosure is governance-neutral and unlikely to influence valuation or liquidity.

Corporate Governance Specialist

TL;DR: Standard board compensation, shows alignment but not strategically significant.

The RSU grant follows the company’s established 2015 Stock Plan, vesting over 12 months, which encourages board retention and shareholder alignment. Indirect holdings through an LLC are properly disclosed, meeting SEC transparency requirements. No red flags emerge regarding excessive compensation or control concentration. The filing is administratively important but strategically non-impactful.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ROSENWALD LINDSAY A MD

(Last) (First) (Middle)

C/O JOURNEY MEDICAL CORPORATION

9237 E VIA DE VENTURA BLVD., SUITE 105

(Street)

SCOTTSDALE AZ 85258

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Journey Medical Corp [ DERM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $0.0001 par value	06/25/2025		A		7,173(1)	A	$0	161,146(2)	D
Common Stock, $0.0001 par value								176,470	I	See Footnote(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On June 25, 2025, the reporting person was granted 7,173 restricted stock units pursuant to the Issuer's 2015 Stock Plan, as amended, which will vest in full on June 25, 2026.

2. Includes restricted stock units, which vest over various time periods.

3. The shares are held by a limited liability company which the reporting person, as managing member, is deemed to have voting and investment power.

	/s/ Ramsey Alloush, attorney-in-fact	07/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Journey Medical (DERM) shares did Dr. Rosenwald acquire?

She received 7,173 restricted stock units, each convertible into one common share upon vesting.

When do the newly granted RSUs vest?

The RSUs vest in full on June 25 2026.

What is Dr. Rosenwald’s total beneficial ownership after the transaction?

She now controls 337,616 Journey Medical shares—161,146 directly and 176,470 indirectly.

Did the Form 4 report any insider sales of DERM stock?

No. The filing shows only an acquisition of RSUs; no shares were sold.

What was the purchase price of the RSUs granted?

The RSUs were granted at $0 as part of equity compensation.